Automated Insulin Delivery: Where Do Ketone Sensors Fit?

How could ketone sensors fit into automated insulin delivery?

Automated insulin delivery combines a glucose sensor, an insulin pump and software that adjusts insulin delivery. Current systems use glucose measurements and trends to guide those adjustments. The American Diabetes Association describes this technology as an established treatment option, with education and troubleshooting support essential to its use. Adding another measurement creates a separate question: how should that information influence treatment? [ADA diabetes technology guidance](https://doi.org/10.2337/dc26-S007).

Abbott says Libre Duo 10 Day is designed for compatibility with leading automated insulin delivery systems and plans a U.S. launch later in 2026. However, that announcement does not establish that every pump can connect to it or that pump algorithms will automatically dose insulin in response to ketones. The practical implication is that compatibility, available functions and treatment instructions must be checked for each combination of devices. [Abbott's product announcement](https://abbott.mediaroom.com/2026-08-25-Abbott-receives-FDA-authorization-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes).

Why do insulin pump users still need a backup treatment plan?

Insulin pumps generally deliver rapid-acting insulin throughout the day. If an infusion set becomes blocked or dislodged, insulin delivery can be interrupted and ketosis can develop. ADA guidance therefore emphasizes recognizing delivery problems and learning how to troubleshoot them. A ketone alert could prompt someone to investigate, but additional software commands cannot make insulin pass through a blocked infusion set. [ADA guidance on insulin pumps](https://doi.org/10.2337/dc26-S007).

A written plan from the diabetes team should explain how to check glucose and ketones, respond to suspected delivery failure, use backup insulin and obtain urgent help. The international consensus report on hyperglycemic crises emphasizes education, access to insulin and monitoring supplies, and clear advice about seeking assistance. Persistent vomiting, difficulty breathing or confusion require urgent medical assessment; waiting for another sensor reading can delay treatment. [Hyperglycemic crises consensus report](https://doi.org/10.2337/dci24-0032).

Does accurate ketone monitoring prove that hospital admissions will fall?

The FDA reported that its review included six clinical studies involving more than 600 participants. These evaluated glucose and ketone monitoring performance, including the ability to track clinically meaningful ketone changes across the sensor's wear period. The announcement did not provide a comparative estimate showing how much the system reduces ketoacidosis admissions. Its findings support monitoring performance without establishing a specific reduction in emergency treatment. [FDA authorization announcement](https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-wearable-device-continuously-monitors-both-ketone-levels-and-blood-sugar).

For insulin pump care, the next research questions include whether alerts lead to timely corrective action, whether they reduce emergency visits and whether users can respond without excessive treatment or alarm burden. These are questions for future evaluation, rather than established benefits. Clinically, an elevated ketone measurement also needs interpretation: diagnosing diabetic ketoacidosis requires assessment of diabetes or hyperglycemia, ketones and metabolic acidosis. A wearable reading alone cannot supply that complete assessment. [International diagnostic consensus](https://doi.org/10.2337/dci24-0032).